一系列基于队列的随机对照试验的总体协议,以测试工具,以将研究结果传达给研究参与者和其他具有相关实践经验的人:SPIN-CLEAR试验
Brett D Thombs1,2,3,4,5, Claire Adams6,7, Elsa-Lynn Nassar6,8
1Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, QC, H4.83H3 T 1E2, Canada. brett.thombs@mcgill.ca.
Trials
|May 9, 2025
概括
向参与者传播研究结果对于信任和未来的参与至关重要. 在SPIN-CLEAR试验系列中,将比较不同的沟通工具,以确定与患者和利益相关者分享研究结果的最有效方法.
科学领域:
- 以患者为中心的研究沟通.
- 临床试验传播策略的传播策略
- 健康素养和参与度
背景情况:
- 对研究结果的有效沟通往往缺乏研究参与者.
- 改善沟通可以增强参与者的理解,信任和未来的研究参与.
- 很少有随机对照试验 (RCT) 比较不同研究沟通工具的有效性.
研究的目的:
- 为了开展结核病以患者为中心的干预网络-传达最新证据和结果 (SPIN-CLEAR) 试验系列.
- 为了比较各种研究沟通工具在向研究参与者和利益相关者传播研究结果的有效性.
- 根据信息的完整性,可理解性和易用性来评估工具的有效性.
主要方法:
- 在多国SPIN队列中将进行一系列并行臂RCT.
- 每个RCT将比较两个或两个以上的传播工具与一个简单的语言摘要比较器.
- 患有系统性硬化症 (SSc) 的参与者将通过不同的工具随机获得研究结果,并使用治疗意图和线性回归模型分析结果.
主要成果:
- 主要目标包括比较信息完整性,可理解性和易用性方面的工具.
- 二次结果包括评估参与者对研究结果的理解以及未来入学研究的可能性.
- 分析将检查各种参与者特征 (例如年龄,性别,健康素养) 的结果.
结论:
- 系列中的每个试验都将建立在之前的发现之上.
- 结果将为研究结果的最佳传播为研究参与者和具有实践经验的个人提供证据基础.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
08:22Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
Published on: October 7, 2017
8.0K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
01:12Hazard Ratio
69
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
69
01:20Comparing the Survival Analysis of Two or More Groups
88
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
88